Paromomycin

Quick links to important sections

Paromomycin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paromomycin

Property Description
Active ingredient Paromomycin sulfate
Form Capsule (oral)
Pharmacological class Aminoglycoside antibiotic, Antiprotozoal
General purpose Clearing specific microbial and parasitic infections in the intestines
Origin Natural product (derived from Streptomyces rimosus var. paromomycinus)

Defining Paromomycin: Class and Composition

Paromomycin is a medication chemically identified as an aminoglycoside antibiotic that also functions as a potent antiprotozoal drug. This dual classification reflects its broad-spectrum activity. The active pharmaceutical ingredient is Paromomycin sulfate, which is typically administered via the oral capsule route. This compound is classified as a natural product, initially isolated from the Streptomyces rimosus bacterium. As a complex amino cyclitol glycoside, Paromomycin sulfate is structurally and functionally related to other established aminoglycoside antibiotics like neomycin.

Paromomycin’s Unique Purpose and Mechanism Focus

Paromomycin is designed to fight infections by disrupting the essential biological processes of targeted pathogens. Its core mechanism of action involves interfering with microbial protein synthesis, which is necessary for the pathogens' growth and reproduction. A key characteristic of oral Paromomycin is that it is poorly absorbed from the gastrointestinal tract. As a result, the medication remains highly localized in the gut. This physiological trait means the medication achieves high concentrations directly within the intestinal lumen. Consequently, the drug’s general benefit is derived from its targeted, localized effect, enabling it to clear out specific infections residing in the gut without relying on significant systemic absorption, a feature utilized when treating intestinal parasitic conditions.

What side effects are possible with Paromomycin?

The safety profile of Paromomycin sulfate oral capsules is determined by its classification as an aminoglycoside antibiotic and its primary mechanism of being poorly absorbed from the gastrointestinal tract.


Officially Documented Adverse Reactions

The most common adverse reactions reported in official regulatory documents are generally localized to the digestive system. These effects, consistent with the drug's high concentration in the gut, include nausea, abdominal cramps, and diarrhea. Other documented G.I. effects may include vomiting and general gastrointestinal intolerance. These localized effects have been reported more frequently at higher daily doses.


Serious Adverse Reactions and Systemic Risks

While systemic absorption is minimal, Paromomycin carries the potential for serious adverse effects associated with the aminoglycoside drug class, which can occur if the drug enters the bloodstream. These risks include Nephrotoxicity (kidney damage) and Ototoxicity (damage to the ear, potentially affecting hearing and balance). The drug is strictly contraindicated in individuals with known hypersensitivity reactions to Paromomycin or other aminoglycosides, and in those with intestinal obstruction.


Safety Considerations for Specific Conditions

Official labeling advises caution when the medication is used in individuals with ulcerative lesions of the bowel. In this specific population, the integrity of the intestinal lining is compromised, which may increase the systemic absorption of the drug and thus increase the risk of systemic toxicities like nephrotoxicity. Furthermore, prolonged administration of the medication is associated with the potential for the overgrowth of non-susceptible organisms, including fungi.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information mandates that an individual who suspects a Paromomycin overdose must seek immediate medical attention. This action is required even if signs of toxicity are not yet apparent, and contact should be made with a healthcare professional or an emergency department.


Documented Overdose Manifestations and Risks

Overdose presentations are primarily characterized by severe local gastrointestinal disturbances, including nausea, vomiting, diarrhea, abdominal cramps, and epigastric burning. These symptoms arise from the high, localized concentration of the drug within the gut.

However, the potential for systemic toxicity carries the risk of serious or life-threatening outcomes, specifically nephrotoxicity (kidney damage) and ototoxicity (damage to hearing and balance), which are recognized risks of the aminoglycoside class.


Officially Described Management

Management Aspect Regulatory Statement
Antidote Availability No specific antidote is documented.
Treatment Focus Management is symptomatic and supportive.
Mandatory Action Immediate discontinuation of the drug upon signs of systemic toxicity.
Monitoring Required Close observation of the patient's hearing function and renal function is necessary.

Population-Specific Considerations

The risk of systemic toxicity is heightened in patients with pre-existing renal insufficiency or those with ulcerative lesions of the bowel, as these conditions can facilitate greater systemic absorption of the drug.

Therapeutic Uses of Paromomycin

Paromomycin: Main Uses and Therapeutic Benefits

Quick Facts

  • Intended Use: Supports the management of certain parasitic and bacterial infections.
  • Key Application 1: Used to address acute and chronic intestinal amebiasis.
  • Key Application 2: Utilized as adjunctive therapy in the management of hepatic coma.

Paromomycin is an antimicrobial agent utilized in the therapeutic management of several specific conditions. Its primary approved indication is to address intestinal amebiasis, which involves a gastrointestinal infection caused by the parasite Entamoeba histolytica. The medication is effective in managing both acute and chronic forms of the infection within the intestinal tract.

The medication also serves as an adjunctive therapeutic measure for the management of hepatic coma (also known as hepatic encephalopathy) in adults. In this context, it contributes to mitigating the symptoms associated with the condition by helping to reduce the growth of intestinal bacteria that produce toxins. Additionally, the agent has been studied and used to address other conditions, including certain tapeworm infestations and the parasite-related disease leishmaniasis. It is important to note that it is not approved for infections that have spread outside the intestine.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Paromomycin

Official Eligibility and Contraindications

Paromomycin is absolutely contraindicated in individuals with a known history of hypersensitivity reactions to the drug itself or to any other aminoglycoside antibiotic. The medicine is also strictly prohibited for use in patients with an existing intestinal obstruction. Some international regulatory labels extend contraindications to patients with severe renal insufficiency, malabsorption syndromes, or certain neuromuscular conditions.

Conditional and Age-Based Restrictions

The medicine must be used with caution in individuals with ulcerative lesions of the bowel. This restriction is officially imposed to prevent unintended systemic absorption of the drug, which increases the potential for renal toxicity. Use may also require caution in patients with kidney disease or impaired hearing.

Regarding age, use is established for adults and pediatric patients for intestinal amebiasis. However, the safety and efficacy of Paromomycin for the management of hepatic coma are not established in the pediatric population. Official guidance notes that the drug should only be used during pregnancy and lactation when clearly needed and with caution, as its effect on the fetus and breastfed infant is not fully established in regulatory data.

What should I know about interactions with other medicines?

The interaction profile for Paromomycin sulfate is defined by its minimal systemic absorption and its primary activity within the gastrointestinal tract, according to official regulatory documentation.

Pharmacodynamic and Exposure Interactions

The label documents that co-administration with other medicinal products known to cause nephrotoxicity or ototoxicity (e.g., certain antibiotics and diuretics) carries a risk of additive toxicity if systemic absorption of Paromomycin unexpectedly increases. Additionally, there is a documented risk of enhanced neuromuscular blockade when the drug is co-administered with neuromuscular-blocking agents.

Paromomycin's high concentration in the gut may cause localized malabsorption, which is officially stated to reduce the systemic exposure of certain co-administered oral medications, including Digoxin and Vitamin B12. Furthermore, co-administration with live bacterial vaccines may result in pharmacodynamic antagonism, diminishing vaccine effectiveness.

Population-Specific Interaction Notes

The risk of systemic toxicity and resultant interaction severity is officially heightened in patient populations with pre-existing conditions. Regulatory sources advise that the presence of ulcerative lesions of the bowel or impaired renal function may lead to greater Paromomycin absorption, which elevates the potential for interactions that rely on systemic drug levels.

Mechanism of Action

Inhibition of Microbial Protein Synthesis

Paromomycin's action involves binding directly to the 16S ribosomal RNA within the 30S ribosomal subunit of susceptible bacteria and protozoa . This specific molecular interaction fundamentally prevents the accurate reading of the genetic code, resulting in the creation of nonfunctional proteins and the subsequent cellular death of the pathogen (bactericidal and amebicidal action).


Localized Action in the Intestinal Lumen

A defining characteristic of Paromomycin's mechanism is its poor systemic absorption, which causes the drug to remain concentrated within the intestinal lumen. This physiological constraint results in a highly concentrated, localized action, allowing the drug to achieve high concentrations precisely at the location of the pathogens, leading to the elimination of susceptible gut-dwelling organisms.


Suppression of Ammonia Production Pathways

The drug's action includes the suppression of specific urease-producing bacteria in the gut, which modulates a key metabolic pathway. By reducing these microbial populations, the mechanism lowers the biological conversion of urea into ammonia, resulting in a decreased production of ammonia within the colon.

Dosage and Administration Information

Paromomycin sulfate is an oral aminoglycoside antibiotic indicated for the treatment of acute and chronic intestinal amebiasis and as adjunctive therapy in the management of hepatic coma. It is important to use this medication exactly as directed by your healthcare provider.

Administration Guidelines

  • Take with Food: Paromomycin capsules should be taken by mouth with meals to aid in administration and potentially reduce gastrointestinal upset.
  • Regular Intervals: Doses should be taken at regularly spaced intervals throughout the day as prescribed to maintain a constant amount of the medication in your system.
  • Complete the Full Course: You must complete the entire prescribed course of therapy, even if your symptoms begin to improve quickly. Stopping the medication early may result in the return of the infection and can lead to the development of drug-resistant bacteria.

Dosage Overview (Must be confirmed by your Doctor)

The dosage of Paromomycin sulfate varies significantly based on the condition being treated and the patient's weight. The following table provides typical dose ranges, but your specific regimen will be determined by your physician:

Condition Typical Adult and Pediatric Dose Duration
Intestinal Amebiasis 25 to 35 mg/kg body weight daily, divided into three doses. 5 to 10 days
Hepatic Coma (Adults) 4 g daily, divided into regular doses. 5 to 6 days

Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.

Storage: Store Paromomycin capsules at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Protect the medication from moisture and keep the container tightly closed, out of reach of children and pets.

Recent Clinical Evidence

Research evidence / Overview of studies for Paromomycin

Evidence for Use in Intestinal Amebiasis

Research has explored Paromomycin in studies examining the Entamoeba histolytica parasite within the gut. Studies examining this condition have included short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily monitored two key outcomes: measures of parasite clearance, which is the confirmed absence of the parasite in stool samples, and the corresponding measures of symptom evolution of physical discomfort and symptoms. The observed populations included both adults and children.

Findings describe patterns observed in these studies, which contribute to the body of evidence concerning non-extraintestinal forms of the disease. What remains uncertain is the lack of research exploring outcomes for infections that have spread outside the intestine (extraintestinal disease). Additionally, limited information exists for long-term outcomes concerning sustained parasite clearance or the potential for recurrence years after the study period.


Evidence for Use in Hepatic Coma (Adjunctive Management)

Paromomycin was studied for its role as an adjunctive therapeutic measure in examining hepatic coma, a complication of severe liver conditions. The research monitored outcomes related to functional imbalance and changes in the clinical grading of encephalopathy in the observed adult populations. The evidence base for this medication was structured around studies that included its use alongside required co-interventions.

What remains uncertain is that research has not formally addressed safety and outcomes in children for the management of hepatic coma. Furthermore, the evidence derived from this setting provides limited insight into its performance as a single agent, as it was studied only in combination with other necessary therapies.


Evidence for Visceral Leishmaniasis

Research has explored Paromomycin in studies examining the parasitic disease leishmaniasis, particularly the visceral form. Researchers examined measures of final outcome (confirmed parasite clearance) and clinical indicators such as changes in fever and reduction in organ size. The highest-level evidence frequently utilized the injectable formulation of Paromomycin. What remains uncertain is the applicability of the high-level findings, as there is limited information about outcomes specifically when using the oral capsule formulation for systemic leishmaniasis.

Key Studies & References

  1. Paromomycin for Dientamoeba fragilis infection (Dientamoebiasis)
  2. Paromomycin in the management of hepatic encephalopathy: Drug Utilization Review Board (DURB) Review

Frequently Asked Questions (FAQ)

Common questions about Paromomycin (FAQ)

Q: How is Paromomycin different from other antibiotics I might have taken for a gut infection?

Paromomycin's action is primarily local, as it is poorly absorbed from the digestive tract and remains concentrated in the intestines. Official product information describes this poor systemic absorption as a defining characteristic, allowing the drug to achieve high concentrations precisely where the susceptible gut pathogens are located.

Q: Are there any specific over-the-counter pain relievers that should be discussed before taking Paromomycin?

Official documentation indicates a risk of additive toxicity when co-administered with other medicines known to cause nephrotoxicity (kidney damage), especially if Paromomycin absorption increases. Because certain over-the-counter pain relievers can belong to this class of medicines, official guidance supports reviewing all concurrent medications with a healthcare professional.

Q: Does Paromomycin interact with common vitamins or herbal supplements?

The official label documents that Paromomycin's local action in the gut may cause localized malabsorption. This action is specifically stated to reduce the systemic exposure of certain co-administered oral medications, including Vitamin B12.

Q: Is Paromomycin related to sulfa drugs or other antibiotic classes that often cause allergies?

According to official product information, Paromomycin is classified as an aminoglycoside antibiotic and is not a sulfa drug. The medication is officially contraindicated for individuals with a known hypersensitivity to Paromomycin or other medicines within the aminoglycoside class.

Q: Why does Paromomycin sometimes cause nausea and vomiting?

Nausea, abdominal cramps, and diarrhea are listed in official adverse reaction data as common side effects. Regulatory sources note that these effects can be more pronounced in patients receiving higher daily doses.

Q: How does Paromomycin differ from Metronidazole (Flagyl), which is also used for some parasite infections?

Paromomycin is primarily defined by its poor systemic absorption, meaning it remains concentrated in the intestines to act locally. Official guidelines for the treatment of certain parasite infections often list Paromomycin and Metronidazole as distinct therapeutic regimens, reflecting their different mechanisms of action and absorption profiles.

Q: Does Paromomycin treat infections caused by viruses like the flu or common cold?

Paromomycin is classified as an antibiotic and is intended to treat specific bacterial or protozoal infections. Official patient guidance states that Paromomycin will not treat an infection caused by a virus, such as the common cold or the flu.

Q: What are the most common side effects of Paromomycin?

The most common side effects reported in official adverse reaction data include nausea, stomach cramps, and mild diarrhea. These effects are typically related to the medication's primary action within the digestive tract.

Q: Are stomach cramps and diarrhea a normal expected side effect of this medicine?

Yes, according to official product information, both stomach cramps and diarrhea are listed among the common adverse effects reported by patients using Paromomycin.

Q: What are some of the more serious but less common side effects associated with Paromomycin?

Serious adverse reactions documented in official sources include signs of a severe allergic reaction and symptoms like watery or bloody diarrhea. There is also a documented risk of ototoxicity (inner ear damage causing hearing or balance issues) if systemic absorption is unexpectedly increased. These effects are generally understood to warrant immediate discussion with a healthcare provider.

Q: Is there a risk of developing a new infection while taking Paromomycin?

Official cautionary statements indicate that prolonged use of Paromomycin may result in the overgrowth of non-susceptible organisms. This action can lead to a fungal or bacterial superinfection.

Q: What is the connection between Paromomycin and C. difficile infections?

Regulatory warnings indicate that the risk of superinfection resulting from prolonged use can specifically include C. difficile-associated diarrhea (CDAD) and related conditions like pseudomembranous colitis.

Q: Is it safe to consume alcohol while undergoing Paromomycin treatment?

General patient guidance from authoritative medical sources suggests discussing the use of alcohol with a healthcare professional while undergoing any drug treatment. This allows a provider to evaluate potential interactions with Paromomycin or the condition being treated.

Q: What are the main health conditions that mean someone cannot use Paromomycin?

According to official product information, Paromomycin is contraindicated in individuals with a known hypersensitivity (allergy) to the drug or other aminoglycosides. It is also contraindicated in patients who have a known or suspected intestinal obstruction.

Q: What are the general guidelines for using Paromomycin during pregnancy?

Official product information notes that due to the drug's poor oral absorption, little of the medication is expected to reach the fetus. Official guidance suggests that use during pregnancy be considered only when the potential benefit is understood to outweigh the potential risk, given the limited human data.

Q: Is Paromomycin known to pass into breast milk?

The official label states that it is not known whether Paromomycin passes into breast milk. However, due to its characteristic poor oral absorption, the amount of the drug that might reach a nursing infant is not expected to be clinically significant, based on the poor absorption.

Q: Are there any age-related safety considerations for older adults (geriatric patients) using Paromomycin?

Patient guidance notes that no specific information is available regarding the relationship of age to the effects of Paromomycin in geriatric patients. However, caution is advised with concurrent use of other agents that may increase toxicity due to common age-related changes in organ function.

Q: What should be done if an allergic reaction to Paromomycin is suspected?

If signs of a severe allergic reaction (such as swelling, hives, or difficulty breathing) are observed or suspected, they should be monitored immediately. Official guidance indicates that a physician should be notified immediately or emergency medical attention should be sought.

Q: Are there different brand names for Paromomycin in different countries?

Yes, Paromomycin is the official generic name. The medicine is sold under the brand name Humatin in the United States and several other countries, as well as under other brand names internationally.

Q: Can Paromomycin be used to treat the condition Dientamoeba fragilis?

Paromomycin is cited by official United States public health guidelines, such as those from the CDC, as a recommended treatment regimen for the parasitic infection Dientamoeba fragilis.

How should Paromomycin be stored and disposed of?

How to Store and Dispose of Paromomycin?

Paromomycin sulfate capsules must be stored at Controlled Room Temperature, which is the range of 20^circ to 25 mathrmC (68^circ to 77 mathrmF). Temporary excursions between 15^circ and 30 mathrmC (59^circ and 86 mathrmF) are permitted. The medication must be protected from moisture and kept in tight containers to maintain its stability. It is mandatory to keep the capsules out of the reach of children and pets.


Disposal Requirements

Unused or expired Paromomycin should be disposed of through an authorized drug take-back program. If a take-back option is unavailable, the product may be disposed of in the household trash by mixing it with an unappealing substance, such as dirt or used coffee grounds, and sealing it in a container. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Paromomycin found in:

A-Z Index: